The recent exchange of letters to the editor, in response to "Time to Reconsider Analgesia in Mass Casualty Incidents" by de Valence and Suppan, 1 has illuminated critical aspects of pain management during mass casualty incidents (MCIs) and brings forth several noteworthy considerations.In all the correspondence, there is an echoing of the overlooked need to address the prioritization of analgesia in injury management, particularly in light of devastating events such as the earthquakes in Turkey, emphasizing the need for timely and effective pain relief in the aftermath of natural disasters. One letter highlights the importance of regional anesthesia as a significant component of analgesia, underscoring its growing relevance in multimodal analgesia management. 2 Another letter proposes the adoption of a new multi-casualty pneumonic triage: START-A. 3 A final letter adds to the discourse by correcting an oversight regarding the availability of Methoxyflurane, stating its approval in Canada since 2018. 4 These clarifications are a valuable update to the original article and underscore the global applicability of specific analgesic options.The main article discusses the historical oversight of analgesia in mass casualty incidents and emphasizes the necessity of reassessing traditional approaches. It advocates for incorporating new, safe, and efficient methods for administering quality analgesia, challenging the prevailing notion of low-priority status for pain management in MCIs. The authors aptly argue that poor pain management in trauma victims can hinder evacuation efforts and contribute to the development of chronic pain and post-traumatic stress disorder. They propose implementing innovative analgesic methods that are easily administered, with rapid onset and minimal need for monitoring, to bridge the gap in providing early pain control during MCIs.These letters and the main article collectively contribute to the ongoing dialogue on the critical role of analgesia in mass casualty incidents. They prompt reevaluating existing paradigms and advocating for integrating novel, efficient, and safe analgesic modalities to enhance patient care in the challenging and dynamic context of MCIs.